983 total citations 34 papers, 822 citations indexed
About
Meyskens Fl is a scholar working on Oncology, Molecular Biology and Genetics.
According to data from OpenAlex, Meyskens Fl has authored 34 papers receiving a total of 822 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 10 papers in Molecular Biology and 5 papers in Genetics. Recurrent topics in Meyskens Fl's work include Cutaneous Melanoma Detection and Management (6 papers), Melanoma and MAPK Pathways (5 papers) and Skin Protection and Aging (4 papers). Meyskens Fl is often cited by papers focused on Cutaneous Melanoma Detection and Management (6 papers), Melanoma and MAPK Pathways (5 papers) and Skin Protection and Aging (4 papers). Meyskens Fl collaborates with scholars based in United States. Meyskens Fl's co-authors include Lippman Sm, Salmon Se, Alberts Ds, B Soehnlen, Lai-Sang Young, Emilio Gil‐Martín, Gallo Rc, Taub Rn, Mikel Aickin and Jones Se and has published in prestigious journals such as PubMed.
In The Last Decade
Meyskens Fl
34 papers
receiving
757 citations
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late)
cites ·
hero ref
This map shows the geographic impact of Meyskens Fl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Meyskens Fl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Meyskens Fl more than expected).
This network shows the impact of papers produced by Meyskens Fl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Meyskens Fl. The network helps show where Meyskens Fl may publish in the future.
Co-authorship network of co-authors of Meyskens Fl
This figure shows the co-authorship network connecting the top 25 collaborators of Meyskens Fl.
A scholar is included among the top collaborators of Meyskens Fl based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Meyskens Fl. Meyskens Fl is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
All Works
20 of 20 papers shown
1.
Fl, Meyskens. (2001). Development of difluoromethyl-ornithine and Bowman-Birk inhibitor as chemopreventive agents by assessment of relevant biomarker modulation: some lessons learned.. PubMed. 154. 49–55.5 indexed citations
2.
Fl, Meyskens. (1992). Strategies for prevention of cancer in humans.. PubMed. 6(2 Suppl). 15–24.7 indexed citations
3.
Fl, Meyskens. (1992). Biomarker intermediate endpoints and cancer prevention.. PubMed. 177–81.12 indexed citations
4.
Fl, Meyskens. (1990). The place of chemoprevention studies in cancer prevention planning.. PubMed. 346. 135–43.1 indexed citations
5.
Fl, Meyskens, et al.. (1989). Chromosome alterations in human malignant melanoma.. PubMed. 11. 165–86.23 indexed citations
6.
Fl, Meyskens, et al.. (1988). Human recombinant alpha- and gamma-interferons enhance the cytotoxic properties of tumor necrosis factor on human melanoma.. PubMed. 7(4). 384–9.6 indexed citations
7.
Fl, Meyskens, et al.. (1985). Clinical-biologic patterns of metastatic melanoma and their effect on treatment.. PubMed. 69(4). 397–401.10 indexed citations
8.
Fl, Meyskens, et al.. (1983). Solar ultraviolet radiation and skin cancer. A public education program.. PubMed. 40(7). 469–72.5 indexed citations
9.
Fl, Meyskens, et al.. (1983). Vitamin A: a potential inhibitor of human cancer.. PubMed. 10(3). 281–9.23 indexed citations
10.
Fl, Meyskens, et al.. (1983). Phase II evaluation of amsacrine (m-AMSA) in solid tumors, myeloma, and lymphoma: a University of Arizona and Southwest Oncology Group Study.. PubMed. 67(7-8). 697–700.8 indexed citations
11.
Fl, Meyskens, et al.. (1983). Phase II trial of the dopaminergic inhibitor pimozide in previously treated melanoma patients.. PubMed. 67(2). 155–7.20 indexed citations
12.
Fl, Meyskens, et al.. (1983). Management of Stage I cutaneous melanoma.. PubMed. 40(11). 768–72.2 indexed citations
13.
Fl, Meyskens, et al.. (1982). Solar ultraviolet radiation and skin cancer. A public education program.. PubMed. 30(4). 516–7, 520.6 indexed citations
14.
Fl, Meyskens, et al.. (1980). Tamoxifen in metastatic malignant melanoma.. PubMed. 64(1). 171–3.17 indexed citations
15.
Se, Salmon, et al.. (1980). Clinical correlations of in vitro drug sensitivity.. PubMed. 48. 223–45.58 indexed citations
16.
Fl, Meyskens, et al.. (1980). The human thymus. II. Partial characterization of thymocytes separated on bovine serum albumin gradients.. PubMed. 2(3). 165–75.1 indexed citations
17.
Fl, Meyskens. (1980). Vitamin A and cancer.. PubMed. 37(2). 84–6.1 indexed citations
18.
Fl, Meyskens, et al.. (1979). Separation of normal human bone marrow cells by counterflow centrifugal elutriation. I. Morphological analysis and subfractionation of neutrophilic granulocytes.. PubMed. 7(8). 401–10.12 indexed citations
19.
Fl, Meyskens, et al.. (1978). Tumor viruses and human cancer. II. DNA tumor viruses.. PubMed. 35(10). 661–2, 666.1 indexed citations
20.
Fl, Meyskens, et al.. (1977). Tumor viruses and human cancer. Leukemia and RNA tumor viruses.. PubMed. 34(11). 763–6.2 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.